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PCardiac Imaging
he Relationship Between Plasma
steoprotegerin Levels and Coronary Artery
alcification in Uncomplicated Type 2 Diabetic Subjects
hakshinamurthy Vijay Anand, MBBS, MRCP,*†‡ Avijit Lahiri, MBBS, MSC, MRCP, FACC, FESC,*
ric Lim, MBCHB, MA, MRCP,* David Hopkins, BSC, MBCHB, FRCP,§
oger Corder, PHD, MRPHARMS†
ondon, United Kingdom
OBJECTIVES This study sought to prospectively evaluate the relationship between plasma osteoprotegerin
(OPG), inflammatory biomarkers (high-sensitivity C-reactive protein [hs-CRP],
interleukin-6 [IL-6], coronary artery calcification (CAC), and cardiovascular events in
patients with type 2 diabetes.
BACKGROUND Arterial calcification is a prominent feature of atherosclerosis and is associated with an
increased risk of cardiovascular events. Osteoprotegerin is a cytokine that has recently been
implicated in the regulation of vascular calcification.
METHODS A total of 510 type 2 diabetic patients (53  8 years; 61% male) free of symptoms of
cardiovascular disease were evaluated by CAC imaging. Risk factors, hs-CRP, IL-6, and
OPG levels were measured. Patients were followed up for cardiovascular events (cardiac
death, myocardial infarction, acute coronary syndrome, late revascularization, and nonhem-
orrhagic stroke).
RESULTS Significant CAC (10 Agatston units) was seen in 236 patients (46.3%); OPG was
significantly elevated in patients with increased CAC. In multivariable analyses, OPG
retained a strong association with elevated CAC scores after adjustment for age, gender, and
other risk factors (odds ratio  2.84, 95% confidence interval 2.2 to 3.67; p  0.01). Sixteen
cardiovascular events occurred during a mean follow-up of 18  5 months. The waist-to-hip
ratio, United Kingdom Prospective Diabetes Study (UKPDS) risk score, OPG level, and
CAC score were significant predictors of time to cardiovascular events in a univariate Cox
proportional hazards model. In the multivariate model, the CAC score was the only
independent predictor of adverse events. Levels of hs-CRP and IL-6 were related to neither
the extent of CAC nor short-term events.
CONCLUSIONS A high proportion of asymptomatic diabetic patients have significant subclinical atheroscle-
rosis. Of the biomarkers studied, only OPG predicted both subclinical disease and near-term
cardiovascular events. Therefore, measurement of OPG merits further investigation as a simple
test for identifying high-risk type 2 diabetic patients. (J Am Coll Cardiol 2006;47:1850–7)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.054© 2006 by the American College of Cardiology Foundation
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(rterial calcification is a prominent feature of atherosclero-
is that can be readily quantified noninvasively by radio-
raphic imaging techniques such as electron beam com-
uted tomography (EBCT) (1). Clinical studies have
eproducibly shown that high amounts of coronary artery
alcification (CAC) predict an increased risk of myocardial
nfarction and sudden coronary death (2). In patients with
iabetes, arterial calcification can occur either as a compo-
ent of atheroma (intimal calcification) or in the absence of
therosclerotic plaque (medial calcification or Monckeberg
clerosis) (3). Medial calcification is related to the severity
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ular Research Trust, GE Healthcare Ltd., and the Derrick Smith research grant. Dr.
ahiri is on the advisory board of GE Healthcare Ltd.t
Manuscript received July 10, 2005; revised manuscript received November 24,
005, accepted December 5, 2005.nd/or duration of diabetes and typically affects arteries that
re less prone to atherosclerosis (4). Although some reports
ave suggested that it may be associated with an increased
isk of cardiovascular complications (5), this is not a
onsistent finding (6). Notably, medial calcification is un-
sual in the coronary arteries, implying that when calcifica-
ion is observed in the coronary arteries, it is almost certainly
ssociated with intimal plaque.
It has been shown that calcification in intimal atheroscle-
otic lesions is not merely a passive consequence of chronic
ascular inflammation but an active process that may lead to
positive feedback loop of calcification and inflammation,
riving atherosclerotic disease progression further (7). Con-
emporary studies have shown similarities between vascular
nd skeletal calcification suggesting a regulatory role for
steogenic and calcitropic factors (8) in the development of
ardiovascular disease. Very recently, osteoprotegerin
OPG), a key factor in bone remodeling, a member of the
umor necrosis factor receptor superfamily (9), and a decoy
r
l
(
a
i
h
s
v
a
o
b
c
v
t
b
C
M
P
p
r
(
t
y
d
i
b
i
t
A
c
k
i
T
m
i
t
t
n
f
(
p
w
a
B
w
a
A
c
O
n
V
i
c
m
7
C
E
f
t
s
p
1
T
t
A
f
c
(
1
a
P
c
t
p
w
e
s
m
d
w
a
e
i
m
c
S
u
l
C
a
r
e
m
P
S
1851JACC Vol. 47, No. 9, 2006 Anand et al.
May 2, 2006:1850–7 Osteoprotegerin and Coronary Calcium in Diabeteseceptor for the receptor activator of nuclear factor-
igand (RANKL), was implicated in human atherogenesis
10). Clinical studies have shown that elevated OPG levels
re associated with the progression of vascular calcification
n patients on long-term hemodialysis (11), growth of
uman abdominal aortic aneurysms (12), the presence and
everity of coronary artery disease (CAD) (13), and cardio-
ascular risk in the general population (14).
Because type 2 diabetes increases the risk of coronary
therosclerosis and cardiovascular events, the objectives of
ur study were: 1) to prospectively evaluate the relationship
etween plasma OPG levels, the extent of coronary artery
alcification (measured by EBCT), and short-term cardio-
ascular events, and 2) to determine the relationship be-
ween OPG and established cardiovascular risk factors,
iomarkers of vascular inflammation (high sensitivity
-reactive protein [hs-CRP] and interleukin [IL]-6).
ETHODS
atients. Asymptomatic type 2 diabetic patients without
rior evidence of cardiovascular disease were prospectively
ecruited from four diabetes clinics in secondary care
Northwest London). Inclusion criteria were presence of
ype 2 diabetes of 1 year duration and age at onset 35
ears. Exclusion criteria were age 35 years or 65 years,
ocumented CAD, typical angina pectoris, abnormal rest-
ng electrocardiogram (e.g., Q waves, left bundle branch
lock), cerebrovascular or peripheral arterial disease, renal
mpairment (creatinine 1.4 mg/dl), or serious life-
hreatening illness. Diabetes was diagnosed according to
merican Diabetes Association criteria. Participants were
onsidered to have type 2 diabetes if they had no history of
etoacidosis and if they did not start insulin treatment either
n the 2 years after diagnosis or before the age of 40 years.
he study was approved by the local research ethics com-
ittees of participating hospitals. Detailed medical history
ncluding the presence of cardiovascular risk factors, dura-
ion of diabetes, presence of microvascular complications,
reatment history, and the predicted 10-year absolute coro-
ary heart disease risk based on the Framingham risk
unction and United Kingdom Prospective Diabetes Study
UKPDS) risk engine (15) were recorded at baseline. A
Abbreviations and Acronyms
AU  Agatston units
CAC  coronary artery calcification
CAD  coronary artery disease
EBCT  electron beam computed tomography
hs-CRP  high-sensitivity C-reactive protein
IL  interleukin
IQR  interquartile range
OPG  osteoprotegerin
OR  odds ratio
UKPDS  United Kingdom Prospective Diabetes Studyhysical examination was performed, and the height, Teight, body mass index, waist-to-hip ratio, blood pressure,
nd a 12-lead electrocardiogram were also obtained.
iochemical measurements. Blood and urine samples
ere obtained for laboratory testing (Diabetes Control
nd Complications Trial [DCCT]-aligned hemoglobin
1c, lipid profile, urea, creatinine, and urine albumin/
reatinine ratio). Serum hs-CRP (ICN Pharmaceuticals,
rangeburg, New York), IL-6 (R&D systems Inc., Min-
eapolis, Minnesota), and plasma OPG levels (Biomedica,
ienna, Austria) (16) were measured by enzyme-linked
mmunosorbent assay. Intra-assay and inter-assay coeffi-
ients of variation for hs-CRP, IL-6, and OPG measure-
ents were 3.3% and 3.7%, 6.4% and 7.8%, and 5% and
.5%, respectively.
AC imaging. The CAC imaging was performed using an
BCT scanner (GE Imatron C-150, San Francisco, Cali-
ornia) equipped with high-resolution detectors. Forty con-
iguous 3-mm slices were obtained at 100-ms scan time per
lice in a single breath-hold, starting at the carina and
roceeding to the level of the diaphragm. Scan time was
00-ms per slice, synchronized to 40% of the R-R interval.
he CAC scores were calculated by an experienced inves-
igator blinded to clinical risk factor information on an
quarius workstation (TeraRecon Inc., San Mateo, Cali-
ornia). Scores were classified into five categories, based on
ut-offs that have been widely used in the literature: 10
minimal or insignificant CAC), 11 to 100 (mild CAC),
01 to 400 (moderate CAC), 401 to 1000 (severe CAC),
nd 1,000 (extensive CAC) (2).
atient management and follow-up. Attending physi-
ians were informed of study results; management was left
o their discretion. Procedures for follow-up were defined a
riori. Telephone interviews and review of medical notes
ere used to determine the occurrence of cardiovascular
vents (cardiac death, myocardial infarction, acute coronary
yndrome [defined by electrocardiographic changes and/or
yocardial markers], late coronary revascularization [60
ays after CAC scan], or nonhemorrhagic stroke). Subjects
ho underwent coronary revascularization within 60 days
fter the CAC scan were excluded from survival analysis to
liminate events that were driven by the results of CAC
maging. In cases in which a study participant experienced
ore than one end point, only the first end point was
ounted.
tatistical analysis. Statistical analyses were carried out
sing the Stata V7 statistical package (Statacorp LP, Col-
ege Station, Texas) or SPSS version 12.0 (SPSS Inc.,
hicago, Illinois). Continuous variables were summarized
s mean  standard deviation or median  interquartile
ange (IQR). Bivariate correlations between OPG levels,
stablished cardiovascular risk factors, and inflammatory
arkers (hs-CRP and IL-6) were performed using the
earson correlation for normally distributed variables and the
pearman rank correlation for variables distributed otherwise.
he distribution of variables was assessed examining the
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Osteoprotegerin and Coronary Calcium in Diabetes May 2, 2006:1850–7requency histograms and the normal plots, and by using the
hapiro-Wilk test. Log transformation was applied to
ormalize the distribution of biomarker values. Ordered
ogistic regression was performed to identify clinical predic-
ors of coronary calcification and evaluate the association
etween OPG and CAC. A backward selection procedure
as applied to identify candidate variables for the multivar-
ate model. Candidate variables included, from the pool of
istorical variables, risk factors, and laboratory variables,
hose univariate predictors with p  0.2. For the multivar-
ate model, only those variables with a p  0.05 were
able 1. Patient Characteristics
Variable Number Percentage
ale 309 60.6
thnicity
Caucasian 110 21.6
South Asian 273 53.5
Black 115 22.5
Other (Chinese/Middle Eastern) 12 2.4
lood pressure 140/90 mm Hg or
antihypertensive medication
380 74.5
reated with blood pressure 140/90 mm Hg 104 20.4
reated with blood pressure 140/90 mm Hg 140 27.4
ntreated (blood pressure 140/90 mm Hg) 136 26.7
yperlipidemia or lipid-lowering medication 318 62.4
reated with total cholesterol 200 mg/dl 133 26.1
reated with total cholesterol 200 mg/dl 64 12.6
ntreated (total cholesterol 200 mg/dl) 121 23.7
amily history of premature CAD 158 31
moking
Past 110 21.6
Current 97 19
nsulin only 57 11.2
nsulin  oral agent 51 10
ral agent 434 85.1
iet only 19 3.7
icroalbuminuria 74 14.5
roteinuria 40 7.8
eripheral neuropathy 90 17.6
etinopathy 116 22.7
Mean SD
ge (yrs) 52.7 8.4
uration of diabetes (yrs) 8 6
MI 28.54 5.04
aist-to-hip ratio 0.94 0.08
AC 6.2* 0–115.8*; 0–5725†
CCT-aligned
hemoglobin A1c (%)
8.2 1.7
otal cholesterol (mg/dl) 187 36
DL cholesterol (mg/dl) 107 31
DL cholesterol (mg/dl) 50 16
riglycerides (mg/dl) 167 104
s-CRP (mg/l) 4.28* 1.72–8.01*
L-6 (pg/ml) 1.93* 1.2–3.1*
steoprotegerin (pmol/l) 6.82* 4.68–11.55*
Median values and interquartile ranges of CAC score, hs-CRP, IL-6, and osteo-
rotegrin. †The overall range of CAC score.
BMI  body mass index; CAC  coronary artery calcification; CAD  coronary
rtery disease; DCCT  Diabetes Control and Complications Trial; HDL 
igh-density lipoprotein; hs-CRP  high-sensitivity C-reactive protein; IL 
nterleukin; LDL  low-density lipoprotein.etained for the final variable selection.
o
fA univariate and multivariate Cox proportional hazards
odel was devised to estimate the time to cardiovascular
vents. From the univariate Cox models, survival curves
ere calculated based on CAC scores and OPG levels. For
his analysis, CAC scores were classified into four catego-
ies, namely 100, 101 to 400, 401 to 1,000, and 1,000
gatston units (AU), and biochemical marker values (hs-
RP, IL-6, and OPG) were classified into tertiles. Addi-
ionally, a receiver operating characteristics curve was plot-
ed for plasma OPG, CAC, and UKPDS and Framingham
isk scores with the end point of cardiovascular events, thus
valuating the ability of each variable to classify the primary
nd point of cardiovascular outcomes. The area under the
urve and 95% confidence intervals were calculated for this
eceiver operating characteristics curve.
ESULTS
he first 510 consecutive patients who fulfilled the eligibil-
ty criteria were enrolled (mean age 53  8 years, 61%
ale). Patient characteristics and biochemical variables are
hown in Table 1.
istribution of CAC. A total of 273 patients (53.5%) had
inimal or insignificant CAC (10 AU). The remaining
36 patients (46.3%) had varying degrees of coronary
alcification. The CAC was mild (11 to 100) in 100 patients
19.6%), moderate (101 to 400) in 77 (15.1%), severe (401
o 1,000) in 31 (6.1%), and extensive (1,000) in 28 (5.5%).
mage quality was poor in one patient because of significant
espiratory motion artifacts.
thnic variation in CAC. There was a high proportion of
outh Asians compared with white Caucasians and black
frican/Caribbeans (Table 1) because of the geographic
ocation of the study population and the high prevalence of
igure 1. Box and whisker plots illustrate the median and interquartile
anges of osteoprotegerin (OPG) in patients with minimal, mild, moder-
te, severe, and extensive coronary calcification respectively. Open circles
how outliers (values between 1.5 and 3 box lengths from the upper edge
f the box) and asterisks show extreme outliers (values 3 box lengths
rom the upper edge of the box).
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May 2, 2006:1850–7 Osteoprotegerin and Coronary Calcium in Diabetesype 2 diabetes in South Asians. Median (interquartile
ange) CAC scores in black African/Caribbeans, South
sians, and Caucasians were 0 (0 to 42.5) AU, 7.2 (0 to
24.3) AU, and 18.8 (0 to 268.4) AU, respectively (p 
.001).
elationship between OPG and CAC scores. The me-
ian level of OPG was 6.82 pmol/l (IQR 4.68 to 11.55).
he OPG levels were significantly elevated in patients with
ncreased CAC (unadjusted odds ratio [OR]  3.08, 95%
able 2. Univariate Predictors of Increased Coronary
alcification: Ordered Logistic Regression Analysis
Variable
Odds Ratio
(95% Confidence Interval)
p
Value
ge* 2.18 (1.76–2.69) 0.001
ender
Female 1
Male 2.64 (1.88–3.71) 0.001
MI 0.96 (0.70–1.32) 0.80
aist-to-hip ratio† 1.67 (1.34–2.07) 0.001
ystolic blood pressure 1.20 (1.09–1.32) 0.001
iastolic blood pressure 1.18 (1.04–1.35) 0.01
yperlipidemia 1.71 (1.21–2.41) 0.002
amily history of premature CAD 1.19 (0.84–1.67) 0.33
moking (pack-yrs)
1–10 yrs 1.23 (0.71–1.82)
10 yrs 2.23 (1.45–3.44) 0.001
uration of diabetes* 1.79 (1.38–2.32) 0.001
icroalbuminuria 1.04 (0.67–1.62) 0.84
etinopathy 1.47 (1.01–2.15) 0.04
eripheral neuropathy 1.43 (0.95–2.15) 0.08
emoglobin A1c 1.00 (0.91–1.10) 0.96
s-CRP (log scale) 0.95 (0.83–1.09) 0.44
L-6 (log scale) 1.02 (0.98–1.06) 0.45
steoprotegerin (log scale) 3.08 (2.42–3.92) 0.001
tatin therapy 1.72 (1.25–2.38) 0.001
ramingham risk score* 1.2 (0.72–1.68) 0.001
KPDS risk score* 1.8 (1.35–2.25) 0.001
Odds ratios are given for a 10-U increase in the explanatory variable. †Odds ratios are
iven for a 0.1-U increase in the explanatory variable.
UKPDS United Kingdom Prospective Diabetes Study; other abbreviations as in
able 1.igure 2. The correlation between markers of inflammation (high-sensitivity C-
oronary calcium (CAC) score. Log transformation was applied to normalize theonfidence interval [CI] 2.42 to 3.92; p  0.001) (Fig. 1).
nivariate predictors of CAC are listed in Table 2. In
ultivariable analyses, OPG levels retained a strong asso-
iation with elevated CAC scores after stepwise adjustment
or age, gender, and other variables such as hypertension,
thnicity, duration of diabetes, and statin use (OR [age- and
ender-adjusted] 2.96 [95% CI 2.34 to 3.78], p 0.01; OR
multivariate adjustment] 2.84 [95% CI 2.2 to 3.67], p 
.01). In contrast, neither hs-CRP nor IL-6 measurements
orrelated with coronary atherosclerotic plaque burden (r 
.02, p not significant for hs-CRP; r 0.09, p 0.03 for
L-6) (Fig. 2).
ssociation between OPG and cardiovascular risk fac-
ors. In agreement with previous studies, OPG levels were
ositively correlated with age as well as waist-to-hip ratio,
ystolic blood pressure, duration of diabetes, and Framing-
am and UKPDS risk scores (Table 3), but not inflamma-
ory biomarkers (hs-CRP, IL-6). Patients with evidence of
icrovascular disease, i.e., retinopathy, peripheral neuropa-
hy, or microalbuminuria, had higher OPG levels in com-
arison with those without (median OPG  7.8 [IQR 5.3
o 13.9] vs. 6.1 [IQR 4.3 to 10.5], p  0.05).
ollow-up. Follow-up was completed in 99.6% of patients
average length of follow up, 18  5 months). A total of 16
ardiovascular events occurred (1 cardiac death, 8 nonfatal
yocardial infarctions, 2 acute coronary syndromes, 2 late
evascularizations, and 3 nonhemorrhagic strokes). No car-
iovascular events occurred in subjects with a CAC 10
U. The majority of events (n  14) occurred in subjects
ith severe CAC (400 AU). The OPG levels were higher
n subjects with events than in those without: 32 (IQR 13.4
o 74.5) vs. 6.8 (IQR 4.7 to 11) (p  0.0001).
The waist-to-hip ratio, UKPDS risk score, OPG level,
nd CAC score were significant predictors of time to
ardiovascular events in a univariate Cox proportional haz-
rd model, whereas age and male gender were of borderline
ignificance (Table 4). Inflammatory biomarkers such asreactive protein [hs-CRP, in mg/l], interleukin [IL]-6 [in pg/ml]) and the
distribution of hs-CRP and IL-6 and to reduce the skew of CAC scores.
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Osteoprotegerin and Coronary Calcium in Diabetes May 2, 2006:1850–7s-CRP and IL-6 were not predictive of short-term cardio-
ascular events. Compared with patients in the lowest OPG
ertile (5.44 pmol/l), the relative risk of a cardiac event
as 5.76 (p  0.01) for patients with OPG levels in the
ighest tertile (9.52 pmol/l) (Fig. 3). In the multivariate
odel, the CAC score was the only independent predictor
f adverse cardiovascular events (Fig. 3).
Receiver-operating characteristic curve analysis (Fig. 4)
howed that the CAC score and plasma OPG level were
etter predictors of short-term cardiovascular risk in com-
arison to the clinically derived UKPDS/Framingham risk
cores (area under the curve values were 0.93, 0.8, 0.75, and
.62 for CAC, OPG, UKPDS, and Framingham risk
cores, respectively [p  0.0001]). The sum of sensitivity
nd specificity for prediction of short-term cardiovascular
vents was maximal at an OPG level of 19 pmol/l
sensitivity 74% [95% CI 48% to 92%], specificity 91%
95% CI 87% to 93%]).
ISCUSSION
ey findings. In this prospective study involving patients
ith uncomplicated type 2 diabetes, we evaluated the
elationship between established risk factors, biochemical
arkers (hs-CRP, IL-6, and OPG), and coronary calcifi-
ation, together with their ability to predict cardiovascular
vents. Key findings were that OPG is correlated with
ardiovascular risk factors (age, waist-to-hip ratio, and
ystolic blood pressure), duration of diabetes, microvascular
isease (retinopathy and peripheral neuropathy), UKPDS/
ramingham risk scores, and extent of calcified coronary
laque. Increasing CAC scores and OPG levels were
ssociated with worsening event-free survival. In contrast,
iomarkers of inflammation (hs-CRP and IL-6) predicted
able 3. Bivariate Correlation Between Plasma Osteoprotegerin
evels and Cardiovascular Risk Factors
Variable
Correlation
Coefficient
p
Value
ge 0.30* 0.0001
MI 0.04* 0.35
aist-to-hip ratio 0.11* 0.01
ystolic blood pressure 0.11* 0.01
iastolic blood pressure 0.03* 0.57
moking (pack-years) 0.07† 0.11
otal cholesterol 0.02* 0.70
DL cholesterol 0.01* 0.93
DL cholesterol 0.06* 0.23
riglycerides 0.06* 0.17
emoglobin A1c 0.01* 0.94
og hs-CRP 0.01* 0.81
og IL-6 0.01* 0.87
uration of diabetes 0.20* 0.0001
ramingham risk score 0.16† 0.0002
KPDS risk score 0.26† 0.0001
Pearson product moment correlation coefficient is calculated for normally distributed
ariables. †Spearman rank correlation coefficient is calculated for variables distributed
therwise.
Abbreviations as in Table 2.either CAC nor near-term cardiovascular events.
gPG and cardiovascular disease. These findings are con-
istent with those from reports showing a close correlation
etween OPG and several major cardiovascular risk factors.
lasma levels of OPG increase with age in men and women
16–18). In a study of 286 healthy Korean women age 37 to
3 years (19), OPG was correlated with age, waist-to-hip
atio, and total and low-density lipoprotein cholesterol and
ollicle-stimulating hormone levels. In another study of 490
aucasian women age 65 years, OPG was shown to be
0% higher in diabetic compared with nondiabetic subjects
20).
Circulating levels of OPG have also been correlated with
urrogate measures of cardiovascular risk including: 1)
arotid intima-media thickness in healthy men and women
14), 2) left ventricular hypertrophy (21), and 3) microvas-
ular disease in diabetic subjects (22). Three cross-sectional
tudies have shown a relationship between OPG levels
nd the severity of coronary atherosclerosis in symptom-
tic CAD patients undergoing coronary angiography
13,21,23). More recently, a small case-controlled study (n
able 4. Univariate Predictors of Cardiovascular Event-Free
urvival, Cox Proportional Hazards Model
Variable
Relative Risk
(95% Confidence Interval)
p
Value
ge* 1.89 (0.92–3.88) 0.08
ender
Female 1
Male 4.30 (0.97–19.1) 0.06
aist-to-hip ratio† 2.25 (1.23–4.13) 0.009
yperlipidemia 0.99 (0.34–2.91) 0.99
amily history of premature CAD 0.77 (0.25–2.43) 0.66
moking (pack-yrs)
1–10 yrs 1.03 (0.32–3.29)
10 yrs 0.33 (0.04–2.61) 0.56
uration of diabetes* 1.66 (0.87–3.17) 0.13
icroalbuminuria 0.86 (0.20–3.83) 0.85
etinopathy 2.12 (0.76–5.96) 0.15
eripheral neuropathy 1.53 (0.49–4.82) 0.47
emoglobin A1c 0.98 (0.72–1.34) 0.90
ramingham risk score* 1.39 (0.83–2.32) 0.21
KPDS risk score* 1.43 (1.12–1.82) 0.004
steoprotegerin
5.44 1
5.45–9.51 1.03 (0.14–7.34)
9.52 5.76 (1.28–26.0) 0.01
s-CRP
2.32 1
2.35–6.62 0.28 (0.06–1.34)
6.62 0.87 (0.29–2.59) 0.27
L-6
1.4 1
1.4–2.7 1.09 (0.35–3.37)
2.7 0.55 (0.14–2.22) 0.61
alcium score
100 1
101–400 9.67 (0.88–105) 0.064
401–1,000 69.22 (8.08–585) 0.0001
1,000 115.37 (14.17–936) 0.0001
Relative risk is given for a 10-U increase in the explanatory variable. †Relative risk is
iven for a 0.1-U increase in the explanatory variable.
Abbreviations as in Table 2.
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May 2, 2006:1850–7 Osteoprotegerin and Coronary Calcium in Diabetes40) has confirmed that OPG is an independent predictor
f silent CAD in asymptomatic diabetic subjects (24).
ecent reports have also established the prognostic value of
PG measurements in healthy men and women (14), and
n patients with heart failure after acute myocardial infarc-
ion (25).
Our report is the first to show that OPG predicts the
xtent of CAC (a surrogate measure of total atherosclerotic
laque burden) in asymptomatic diabetic patients. Prelimi-
ary data from the population based Multi-Ethnic Study of
therosclerosis (MESA) are consistent with our observa-
igure 3. Event-free survival at 18 5 months by the Cox proportional haz
steoprotegerin (OPG) level (B), respectively. RR  relative risk ratio.
igure 4. Receiver-operating characteristic curve analysis showing the
rognostic value of coronary calcium (CAC) scores, osteoprotegerin
OPG) levels, and United Kingdom Prospective Diabetes Study (UKPDS)(
nd Framingham risk scores in predicting cardiovascular events. The 95%
onfidence intervals are provided. AUC  area under the curve.ions (26). In addition, we have also confirmed the prog-
ostic value of elevated OPG levels in this population.
PG and vascular calcification. Several key regulators of
one formation and bone structural proteins have recently
een detected in atherosclerotic plaques (8). The RANKL/
ANK/OPG system is emerging as an important regulator
f vascular, immune, and skeletal biology (9,10). Genetically
ltered mice unable to express functional OPG show both
steoporosis and arterial calcification in the aorta and large
rteries (27). Interestingly, the intravenous injection of
ecombinant OPG protein and the transgenic overexpres-
ion of OPG have been shown to reverse osteoporosis and
revent vascular calcification (28). Furthermore, it has been
hown that administration of recombinant OPG to rats is
ble to inhibit arterial calcification induced by warfarin and
itamin D (29). Data from experimental studies indicate
hat pro-inflammatory cytokines such as tumor necrosis
actor-alpha and IL-6 induce OPG expression in smooth
uscle and endothelial cells, and OPG in turn modulates
arious inflammatory signaling pathways (10,12).
All of the above clinical and experimental data suggest
n active role for OPG in vascular pathophysiology, but
t is not immediately apparent whether OPG is beneficial
r injurious to the vasculature. When elevated in patients
ith atherosclerosis, OPG levels clearly seem to indicate
he overall burden of disease (13,14,21,23). This may be
ecause OPG is protective and counterregulatory, as
roposed by Browner, et al. (20) and others (14), or it
ay simply reflect the level of vascular inflammatory
rocesses that underlie the development and evolution of
therosclerotic lesions in patients with extensive disease
odel according to the extent of coronary calcification level (A) and plasma10,12).
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howing the relationship between hs-CRP and cardiovas-
ular risk (30), it did not predict near-term cardiovascular
vents in our study. Consistent with previous reports,
owever, we found a lack of correlation between CAC
cores and hs-CRP (31,32). This may be because they
eflect different pathologic processes, i.e., whereas the CAC
core is a surrogate marker of the total atherosclerotic plaque
urden, hs-CRP seems to provide an assessment of athero-
clerotic plaque activity/stability. Overall levels of both
s-CRP and IL-6 were high in this population, and it is
ossible that inflammation has a permissive role in deter-
ining coronary artery plaque volume or stability but that
ther factors are responsible for driving these processes.
upporting this notion, recent reports have suggested that
he predictive value of hs-CRP is relatively modest in
omparison with conventional risk factors (33). Because this
tudy was only powered to detect strong risk associations, it
oes not negate the prognostic value of hs-CRP or IL-6. It
erely shows that CAC and plasma OPG are significantly
etter predictors of short-term CAD risk in this patient
roup. Our findings are also consistent with data from
chulze et al. (34), who found that hs-CRP levels did not
redict cardiovascular events at 18 months in asymptomatic
iabetic men, and only became an independent predictor of
ardiovascular survival by 5 years.
tudy limitations. Attending physicians were informed of
AC results, which may have biased treatment received and
ssessment of outcome. However, it was not thought ethical
o withhold this information given the emerging data on its
rognostic power in the general population. Because of the
omparatively short follow-up period, both hard and soft
nd points were included in the analysis. Nevertheless, there
ere nine hard events, including eight myocardial
nfarctions.
onclusions. A high proportion (46.3%) of asymptom-
tic patients with type 2 diabetes have significant coro-
ary atherosclerosis based on coronary calcium imaging.
he extent of CAC was a powerful predictor of cardio-
ascular event-free survival. Of the biochemical markers
tudied, only elevated OPG levels predicted subclinical
therosclerosis and near-term cardiovascular events.
ince conventional risk factors and inflammatory biomar-
ers do not provide adequate risk stratification in diabetic
ubjects, measurement of plasma OPG merits further
nvestigation as a simple test for identifying high-risk
ndividuals.
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